RxDoctor Payments Data

William Damsky, PhD

Dermatology · New Haven, CTNPI 1871938381

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,685 of the $22,927 with a category attached, or 64.0%. 12 manufacturers reported payments, led by Incyte Corporation at 40.8% of the total. Reporting peaked in 2024 at $9,429 and has fallen 99.5% since, to $48 in 2025.

$22,927in general payments, 2019–2025

Across 34 payments — averaging $674.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$9K
  • Pfizer$6K
  • Fresenius Kabi USA, LLC$3K
  • Boehringer Ingelheim$2K
  • Sanofi-aventis U.S. LLC$1K
  • Vertex$393
  • plus $514 from 6 others
$1,008,594in research payments, 2019–2025

Across 6 payments — averaging $168,099 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$994K
  • E.r. Squibb & Sons, L.L.C.$15K

What the payments were for

  • Consulting fees$14,68564%
  • Speaking & faculty fees$6,00026%
  • Travel & lodging$1,1505%
  • Food & beverage$1,0114%
  • Education$820%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,927 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$47,603
Medicare patients
214
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab161$593,792
Humira(Cf) PenAdalimumab23$307,433
OlumiantBaricitinib50$247,723
RinvoqUpadacitinib27$170,316
Dupixent SyringeDupilumab16$118,357
AdbryTralokinumab-Ldrm24$92,530
XeljanzTofacitinib Citrate15$84,148
OtezlaApremilast16$77,050
OpzeluraRuxolitinib Phosphate19$71,000
Clobetasol Propionate143$3,829
Tacrolimus18$3,820
Acitretin20$3,799
Minoxidil104$1,867
Fluocinolone Acetonide11$1,325
Fluorouracil21$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$83$247,72350 claims
PfizerXeljanz$6,164$84,14815 claims
Incyte CorporationOpzelura$9,361$71,00019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 dermatology providers in Connecticut.

Other dermatology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →